Back to Top
Atoltivimab Biosimilar - Research Grade
Frequently Bought Together
Loading...
Atoltivimab Biosimilar - Research Grade
Endotoxin
≤ 1.0 EU/mg as determined by the LAL method
Purity
>90% by SDS-PAGE
Species Reactivity
Human
Target
Zaire Ebola virus
Concentration
>1mg/ml
Isotype
IgG1 - kappa
Host
CHO Cells
Antibodies Against The Same Target
Sequence
https://www.imgt.org/mAb-DB/
Buffer
ICH3002
Shipping Conditions
Blue ice
Background
The Zaire Ebola virus glycoprotein mediates host-cell entry and is the principal antigen for filovirus neutralization and biodefence research. This anti-Ebola virus recombinant monoclonal antibody is supplied as an unconjugated, non-therapeutic analog of atoltivimab for research use only. Produced to rigorous in vivo standards and purified to low endotoxin, it is manufactured in scalable milligram (mg) to gram (g) quantities to serve bulk and high-throughput laboratories. The reagent is well suited to viral-neutralization and binding assays, in vitro functional screening, and in vivo infectious-disease models, providing dependable, reproducible performance.
Purification Method
This monoclonal antibody was purified using Protein A
Formulation
Sterile, preservative-free, solution in PBS. BSA and Azide free.
Storage
This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.
Applications
Functional Assays
Application Notes
This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.
Use
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Delivery Time
3-4 weeks
Faq (q&a)
Q: Is the Atoltivimab biosimilar available in gram quantities?
A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.
Q: Is this research-grade Atoltivimab biosimilar suitable for in vivo studies?
A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).
Q: What does the Atoltivimab biosimilar target?
A: It is an unconjugated, non-therapeutic analog of Atoltivimab that binds Zaire Ebola virus.
Write Your Own Review
Is the Atoltivimab biosimilar available in gram quantities?
Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.
Is this research-grade Atoltivimab biosimilar suitable for in vivo studies?
Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).
What does the Atoltivimab biosimilar target?
It is an unconjugated, non-therapeutic analog of Atoltivimab that binds Zaire Ebola virus.
Who Viewed This Also Viewed
Add recommended extras
-
In Vivo Buffer pH7.2$112.50
